Navigation Links
Labopharm to present at Cowen 30th Annual Health Care Conference
Date:3/3/2010

LAVAL, QC, March 3 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that James R. Howard-Tripp, President and Chief Executive Officer of the Company, will present at the Cowen and Company 30th Annual Health Care Conference at The Boston Marriott Copley Place, on Tuesday, March 9, 2010 at 1:30 p.m. ET.

Interested parties may access the live webcast for this presentation by visiting the "Events" section of the homepage of the Company's website at www.labopharm.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An audio archive of the presentation will be available for 30 days.

About Labopharm Inc.

Headquartered in Laval, Canada with US offices in Princeton, New Jersey, Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. Its second product, OLEPTRO(TM), a novel formulation of trazodone for the treatment of major depressive disorder in adults, has received regulatory approval in the U.S. and is under regulatory review in Canada. Labopharm has initiated the European regulatory approval process for its third product, a twice-daily formulation of tramadol-acetaminophen. The Company also has a pipeline of follow-on products in both pre-clinical and clinical development.

SOURCE Labopharm Inc.

Back to top
'/>"/>
SOURCE Labopharm Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm announces underwriters exercise of over-allotment option for recent public offering
2. Labopharm announces closing of US$20 million public offering of units
3. Labopharm announces pricing of US$20 million public offering of units
4. Labopharm settles $1 million draw down under standby equity distribution agreement
5. Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe
6. Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement
7. Labopharm Reports Results for Third Quarter Fiscal 2009
8. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
9. Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
10. Labopharm submits response to FDA for novel antidepressant
11. Labopharm Reports Results for Second Quarter Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose ... – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose ... products, garnering increased attention from all stakeholders in the development of new chemical ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a technology and ... the ISE Southeast Awards 2016. Finalists and winners of the ISE® Awards for ... Forum and Awards Gala on March 15, 2016 at the Westin Peachtree Plaza, ...
(Date:2/12/2016)... Las Vegas, NV (PRWEB) , ... February 12, 2016 , ... ... of North Las Vegas Mayor John J. Lee, Nevada Military Support Alliance president Scott ... newest Fisher House at the VA Southern Nevada Healthcare System. This will be ...
(Date:2/12/2016)... ... February 12, 2016 , ... Erlanger Agency has announced a new partnership in ... latest campaign focuses on the fight against breast cancer, fundraising for a local woman ... here . , Carmen is a loving single mother of two boys who also ...
(Date:2/12/2016)... ... February 12, 2016 , ... For Coast Dental dentist Everet Lake, DDS, ... dental assistant Terrell Moore shortly before 7 a.m. to volunteer at Friday’s Dentistry from ... their time and skills to help hundreds of uninsured and underinsured people receive much-needed ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... DPLO ) is pleased to announce the promotion of Paul Urick to Senior Vice ... To learn more about our Diplomat executive team, click ... ... ... In his redefined role at Diplomat, Urick ...
(Date:2/12/2016)... , Feb. 12, 2016   HeartWare International, ... conference call and webcast to discuss its financial results ... 2015, on Thursday, February 25, 2016 at 8:00 a.m. ... prior to the conference call and webcast.  On the ... financial results, highlights from the fourth quarter and business ...
(Date:2/12/2016)... , Feb. 12, 2016  Sequent Medical, Inc. ... a study to evaluate the safety and effectiveness of ... treatment of ruptured intracranial aneurysms.  Prof Laurent Spelle ... in Paris, France and Principal ... France and Germany.  Although ...
Breaking Medicine Technology: